© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 21, 1626-1634,
November 6, 2002
© 2002 Oxford University Press
ARTICLE |
Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975–1999
Affiliations of authors: A. Mariotto, E. J. Feuer, L. C. Harlan, L.-M. Wun (Division of Cancer Control and Population Sciences), K. A. Johnson (Division of Cancer Prevention), J. Abrams (Division of Cancer Treatment and Diagnosis), National Cancer Institute, National Institutes of Health, Bethesda, MD.
Correspondence to: Angela Mariotto, Ph.D., National Cancer Institute, 6116 Executive Blvd., Suite 504 MSC 8317, Bethesda, MD 20892–8317 (e-mail: mariotta{at}mail.nih.gov).
Background: Understanding trends in the dissemination of findings from clinical research can help in estimating their population-level benefits. We evaluated trends in the use of adjuvant multi-agent chemotherapy, tamoxifen, and the combination of both treatments for early-stage breast cancer in the United States from 1975 through 1999. Methods: Data on treatment of 217 508 patients diagnosed from 1975 through 1999 with stages I, II, and IIIA breast cancer were obtained from eight registries of the Surveillance, Epidemiology, and End Results (SEER) Program. Models of dissemination were developed from these data after adjustment based on information from a series of population-based Patterns of Care (POC) studies that randomly selected case patients from the SEER registries. The POC studies included 7116 patients diagnosed from 1987 through 1991 and in 1995 who were eliminated from the SEER data used in this analysis. Results: The modeled disseminations were generally compatible with the POC-observed proportions of each treatment. The use of multi-agent chemotherapy was higher among premenopausal women, and the use of tamoxifen was higher among postmenopausal women. The use of multi-agent chemotherapy for postmenopausal women diagnosed with lymph node-positive stage II+ or stage IIIA cancer reached a peak in 1983 and then decreased through 1986, indicating its substitution with tamoxifen. After 1986, the combined use of multi-agent chemotherapy and tamoxifen increased for almost all stages and ages. After the early 1990s, tamoxifen use in postmenopausal women with stage II+ or stage III breast cancer declined. Conclusions: The observed dissemination patterns suggest that the results of clinical trials are disseminated fairly rapidly to community-based physicians and their patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. N.A. Tosteson, N. K. Stout, D. G. Fryback, S. Acharyya, B. A. Herman, L. G. Hannah, E. D. Pisano, and for the DMIST Investigators Cost-Effectiveness of Digital Mammography Breast Cancer Screening Ann Intern Med, January 1, 2008; 148(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Vanderveen, D. A. Paterniti, R. L. Kravitz, and R. J. Bold Diffusion of Surgical Techniques in Early Stage Breast Cancer: Variables Related to Adoption and Implementation of Sentinel Lymph Node Biopsy Ann. Surg. Oncol., May 1, 2007; 14(5): 1662 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Jatoi, B. E. Chen, W. F. Anderson, and P. S. Rosenberg Breast Cancer Mortality Trends in the United States According to Estrogen Receptor Status and Age at Diagnosis J. Clin. Oncol., May 1, 2007; 25(13): 1683 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Aziz, S. Gardner, K. Pritchard, L. Paszat, and C. M. B. Holloway Selective Application of Axillary Node Dissection in Elderly Women with Early Breast Cancer Ann. Surg. Oncol., February 1, 2007; 14(2): 652 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Feuer Chapter 1: Modeling the Impact of Adjuvant Therapy and Screening Mammography on U.S. Breast Cancer Mortality Between 1975 and 2000: Introduction to the Problem J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 2 - 6. [Full Text] [PDF]
|
|
|
|
|
|
A. B. Mariotto, E. J. Feuer, L. C. Harlan, and J. Abrams Chapter 2: Dissemination of Adjuvant Multiagent Chemotherapy and Tamoxifen for Breast Cancer in the United States Using Estrogen Receptor Information: 1975-1999 J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 7 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. R. Holford, K. A. Cronin, A. B. Mariotto, and E. J. Feuer Chapter 4: Changing Patterns in Breast Cancer Incidence Trends J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 19 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Berry, L. Inoue, Y. Shen, J. Venier, D. Cohen, M. Bondy, R. Theriault, and M. F. Munsell Chapter 6: Modeling the Impact of Treatment and Screening on U.S. Breast Cancer Mortality: A Bayesian Approach J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 30 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mandelblatt, C. B. Schechter, W. Lawrence, B. Yi, and J. Cullen Chapter 8: The SPECTRUM Population Model of the Impact of Screening and Treatment on U.S. Breast Cancer Trends From 1975 to 2000: Principles and Practice of the Model Methods J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 47 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lee and M. Zelen Chapter 11: A Stochastic Model for Predicting the Mortality of Breast Cancer J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 79 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Plevritis, B. M. Sigal, P. Salzman, J. Rosenberg, and P. Glynn Chapter 12: A Stochastic Simulation Model of U.S. Breast Cancer Mortality Trends From 1975 to 2000 J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 86 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. F. Habbema, C. B. Schechter, K. A. Cronin, L. D. Clarke, and E. J. Feuer Chapter 16: Modeling Cancer Natural History, Epidemiology, and Control: Reflections on the CISNET Breast Group Experience J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 122 - 126. [Full Text] [PDF]
|
|
|
|
|
|
S. Paik, G. Tang, S. Shak, C. Kim, J. Baker, W. Kim, M. Cronin, F. L. Baehner, D. Watson, J. Bryant, et al. Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., August 10, 2006; 24(23): 3726 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Giordano, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, and J. S. Goodwin Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2750 - 2756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Elkin, A. Hurria, N. Mitra, D. Schrag, and K. S. Panageas Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptor-Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort J. Clin. Oncol., June 20, 2006; 24(18): 2757 - 2764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Stout, M. A. Rosenberg, A. Trentham-Dietz, M. A. Smith, S. M. Robinson, and D. G. Fryback Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst, June 7, 2006; 98(11): 774 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Richardson, L. Tian, L. Voti, A. G. Hartzema, I. Reis, L. E. Fleming, and J. MacKinnon The Roles of Teaching Hospitals, Insurance Status, and Race/Ethnicity in Receipt of Adjuvant Therapy for Regional-Stage Breast Cancer in Florida Am J Public Health, January 1, 2006; 96(1): 160 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Jatoi, W. F. Anderson, S. R. Rao, and S. S. Devesa Breast Cancer Trends Among Black and White Women in the United States J. Clin. Oncol., November 1, 2005; 23(31): 7836 - 7841. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Berry, K. A. Cronin, S. K. Plevritis, D. G. Fryback, L. Clarke, M. Zelen, J. S. Mandelblatt, A. Y. Yakovlev, J. D. F. Habbema, E. J. Feuer, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med., October 27, 2005; 353(17): 1784 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. L. Du, D. V. Jones, and D. Zhang Effectiveness of Adjuvant Chemotherapy for Node-Positive Operable Breast Cancer in Older Women J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2005; 60(9): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Brenner and V. Arndt Further Enhanced Monitoring of Cancer Patient Survival by Stage-Adjusted Period Analysis Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1917 - 1921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bosetti, M. Malvezzi, L. Chatenoud, E. Negri, F. Levi, and C. La Vecchia Trends in cancer mortality in the Americas, 1970-2000 Ann. Onc., March 1, 2005; 16(3): 489 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Buzdar and C. Macahilig How Rapidly Do Oncologists Respond to Clinical Trial Data? Oncologist, January 1, 2005; 10(1): 15 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J Feuer, R. Etzioni, K. A Cronin, and A. Mariotto The use of modeling to understand the impact of screening on US mortality: examples from mammography and PSA testing Statistical Methods in Medical Research, December 1, 2004; 13(6): 421 - 442. [Abstract] [PDF]
|
|
|
|
|
|
J. Cuzick, A. Buzdar, M. Baum, R. Bianco, R. Coleman, M. Constenla, W. Distler, M. Dowsett, J. Forbes, J. P. Guastalla, et al. Adjuvant Use of Anastrozole in Breast Cancer J. Clin. Oncol., April 15, 2004; 22(8): 1524 - 1526. [Full Text]
|
|
|
|
 |
|
 A. U. Buzdar Data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial: Implications for Use of Aromatase Inhibitors in 2003 Clin. Cancer Res., January 1, 2004; 10(1): 355S - 361S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Harlan, L. X. Clegg, and J. L. Warren Chemotherapy in Women with Breast Cancer Ann Intern Med, November 18, 2003; 139(10): 868 - 868. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ghafoor, A. Jemal, E. Ward, V. Cokkinides, R. Smith, and M. Thun Trends in Breast Cancer by Race and Ethnicity CA Cancer J Clin, November 1, 2003; 53(6): 342 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Weir, M. J. Thun, B. F. Hankey, L. A. G. Ries, H. L. Howe, P. A. Wingo, A. Jemal, E. Ward, R. N. Anderson, and B. K. Edwards Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control J Natl Cancer Inst, September 3, 2003; 95(17): 1276 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. L. Du Re: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999 J Natl Cancer Inst, May 7, 2003; 95(9): 683 - 683. [Full Text] [PDF]
|
|
|
|
|
|
A. Mariotto, E. J. Feuer, and J. Abrams RESPONSE: Re: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999 J Natl Cancer Inst, May 7, 2003; 95(9): 684 - 685. [Full Text] [PDF]
|
|
|
|
|
|
V. C. Jordan and M. Morrow Re: Trends in Use of Adjuvant Multi-Agent Chemotherapy and Tamoxifen for Breast Cancer in the United States: 1975-1999 J Natl Cancer Inst, May 7, 2003; 95(9): 683 - 684. [Full Text] [PDF]
|
|